Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Equivalence of CHF5993 pMDI with HFA-152a vs HFA-134a in Mild to Moderate Asthma
NCT07301736Phase 2Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in asthma, sponsored by Chiesi Farmaceutici S.p.A.. Started Dec 2025; status: recruiting.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07301736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301736.